Marnie Graco1,2, Sally E Green3, Julie Tolson4, Bronwyn Stevens4, Maree Barnes4,5, Alyssa Rigoni4, Sandra Henderson4, Carmel Nicholls4, David J Berlowitz4,6. 1. Institute for Breathing and Sleep, Austin Health, Melbourne, Victoria, Australia. marnie.graco@austin.org.au. 2. The University of Melbourne, Department of Medicine, Melbourne, Victoria, Australia. marnie.graco@austin.org.au. 3. Monash University, School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia. 4. Institute for Breathing and Sleep, Austin Health, Melbourne, Victoria, Australia. 5. The University of Melbourne, Department of Medicine, Melbourne, Victoria, Australia. 6. The University of Melbourne, Department of Physiotherapy, Melbourne, Victoria, Australia.
Abstract
STUDY DESIGN: Mixed methods OBJECTIVES: Continuous positive airway pressure (CPAP) therapy is the recommended treatment for obstructive sleep apnoea (OSA). The aim of this study was to estimate CPAP adherence in people with tetraplegia and OSA, and to explore the barriers and facilitators to CPAP use. SETTING: Hospital outpatient department in Melbourne, Australia METHODS: People with chronic tetraplegia and OSA were commenced with auto-titrating CPAP and supported for 1 month. Semi-structured interviews were conducted with participants at one month and analysed thematically. CPAP usage was measured at 1, 6 and 12 months, with "adherent" defined as achieving more than 4 h average per night. RESULTS: Sixteen participants completed the study (80% male; mean age 56 (SD = 15)). Mean nightly CPAP use at one month was 3.1 h (SD = 2.5; 38% adherent), and at 6 months and 12 months were 2.6 h (SD = 2.8; 25% adherent) and 2.1 h (SD = 3.2; 25% adherent). The perceived benefit/burden balance strongly influenced ongoing use. Burden attributed to CPAP use was common, and included mask discomfort, and physical and emotional problems. Adherent participants were motivated by the immediate daytime benefits to mood, alertness and sleepiness. There was a tendency to not recognise symptoms of OSA until after they were treated. CONCLUSION: CPAP use is challenging for people with tetraplegia, who experience substantial burden from using the device. When tolerated, the proximate benefits are substantial. People with tetraplegia need more intensive support for longer to help them overcome the burdens of CPAP and benefit from the treatment.
STUDY DESIGN: Mixed methods OBJECTIVES: Continuous positive airway pressure (CPAP) therapy is the recommended treatment for obstructive sleep apnoea (OSA). The aim of this study was to estimate CPAP adherence in people with tetraplegia and OSA, and to explore the barriers and facilitators to CPAP use. SETTING: Hospital outpatient department in Melbourne, Australia METHODS:People with chronic tetraplegia and OSA were commenced with auto-titrating CPAP and supported for 1 month. Semi-structured interviews were conducted with participants at one month and analysed thematically. CPAP usage was measured at 1, 6 and 12 months, with "adherent" defined as achieving more than 4 h average per night. RESULTS: Sixteen participants completed the study (80% male; mean age 56 (SD = 15)). Mean nightly CPAP use at one month was 3.1 h (SD = 2.5; 38% adherent), and at 6 months and 12 months were 2.6 h (SD = 2.8; 25% adherent) and 2.1 h (SD = 3.2; 25% adherent). The perceived benefit/burden balance strongly influenced ongoing use. Burden attributed to CPAP use was common, and included mask discomfort, and physical and emotional problems. Adherent participants were motivated by the immediate daytime benefits to mood, alertness and sleepiness. There was a tendency to not recognise symptoms of OSA until after they were treated. CONCLUSION: CPAP use is challenging for people with tetraplegia, who experience substantial burden from using the device. When tolerated, the proximate benefits are substantial. People with tetraplegia need more intensive support for longer to help them overcome the burdens of CPAP and benefit from the treatment.
Authors: Jacinthe J E Adriaansen; Marcel W M Post; Sonja de Groot; Floris W A van Asbeck; Janneke M Stolwijk-Swüste; Marga Tepper; Eline Lindeman Journal: J Rehabil Med Date: 2013-11 Impact factor: 2.912
Authors: David T Eton; Kathleen J Yost; Jin-Shei Lai; Jennifer L Ridgeway; Jason S Egginton; Jordan K Rosedahl; Mark Linzer; Deborah H Boehm; Azra Thakur; Sara Poplau; Laura Odell; Victor M Montori; Carl R May; Roger T Anderson Journal: Qual Life Res Date: 2016-08-26 Impact factor: 4.147
Authors: Amir Qaseem; Jon-Erik C Holty; Douglas K Owens; Paul Dallas; Melissa Starkey; Paul Shekelle Journal: Ann Intern Med Date: 2013-10-01 Impact factor: 25.391
Authors: Anne Buzzell; Jonviea D Chamberlain; Martin Schubert; Gabi Mueller; David J Berlowitz; Martin W G Brinkhof Journal: J Spinal Cord Med Date: 2020-01-24 Impact factor: 1.985